Recent ADIL News
- Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 • GlobeNewswire Inc. • 04/29/2026 01:07:00 PM
- Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program • GlobeNewswire Inc. • 04/27/2026 12:47:00 PM
- Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial • GlobeNewswire Inc. • 04/22/2026 01:35:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 09:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:04 PM
- Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans • GlobeNewswire Inc. • 03/24/2026 01:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:15:35 PM
- Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/06/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2026 10:03:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 01:17:24 PM
- Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement • GlobeNewswire Inc. • 03/03/2026 01:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 02:06:05 PM
- Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement • GlobeNewswire Inc. • 02/24/2026 02:00:00 PM
- Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One • GlobeNewswire Inc. • 02/23/2026 01:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 04:06:49 PM
- Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/17/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 09:30:34 PM
- Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 • GlobeNewswire Inc. • 02/04/2026 02:35:00 PM
- Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 • GlobeNewswire Inc. • 01/14/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 09:15:54 PM
